Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren's syndrome in Taiwan

Meng Yu Weng, Yu Tung Huang, Ming Fei Liu, Tsung Hsueh Lu

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Objective: Patients with primary Sjögren's syndrome (pSS) are at a higher risk of developing non-Hodgkin's lymphoma (NHL). However, little is known with regard to the risk of developing cancers other than NHL. The authors aimed in this study to compare the incidence of cancer in various sites among patients with pSS with the general population of Taiwan. Methods: The authors used National Health Insurance claims data to establish a nationwide population cohort of 7852 patients with pSS from 2000 to 2008 who did not have cancer prior to diagnosis of pSS. Incidence and standardised incidence ratios (SIRs) for cancer in various sites were calculated. Results: Among patients with pSS, 277 (2.9%) developed cancer. The SIR for cancer was 1.04 (95% CI 0.91 to 1.18) among patients of all ages with pSS and was 2.19 (95% CI 1.43 to 3.21) for patients aged 25-44 years. Female patients with pSS had a higher risk of NHL (SIR 7.1, 95% CI 4.3 to 10.3), multiple myeloma (SIR 6.1, 95% CI 2.0 to 14.2) and thyroid gland cancer (SIR 2.6, 95% CI 1.4 to 4.3) and a lower risk of colon cancer (SIR 0.22, 95% CI 0.05 to 0.65). In contrast, male patients with pSS were not at a higher risk of developing cancer in particular sites. Conclusion: Patients with pSS, overall, did not have higher risk of cancer, and only patients aged 25-44 years were at an increased risk of cancer compared with their counterparts in the general population. Cancer screening for patients with pSS, especially female patients, should focus on NHL and multiple myeloma and thyroid gland cancer.

Original languageEnglish
Pages (from-to)524-527
Number of pages4
JournalAnnals of the Rheumatic Diseases
Volume71
Issue number4
DOIs
Publication statusPublished - 2012 Apr 1

Fingerprint

Taiwan
Incidence
Population
Neoplasms
Non-Hodgkin's Lymphoma
Health insurance
Multiple Myeloma
Thyroid Neoplasms
Thyroid Gland
Screening
National Health Programs
Early Detection of Cancer
Colonic Neoplasms

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{b646295df76b416d80330bb1ef617fcd,
title = "Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sj{\"o}gren's syndrome in Taiwan",
abstract = "Objective: Patients with primary Sj{\"o}gren's syndrome (pSS) are at a higher risk of developing non-Hodgkin's lymphoma (NHL). However, little is known with regard to the risk of developing cancers other than NHL. The authors aimed in this study to compare the incidence of cancer in various sites among patients with pSS with the general population of Taiwan. Methods: The authors used National Health Insurance claims data to establish a nationwide population cohort of 7852 patients with pSS from 2000 to 2008 who did not have cancer prior to diagnosis of pSS. Incidence and standardised incidence ratios (SIRs) for cancer in various sites were calculated. Results: Among patients with pSS, 277 (2.9{\%}) developed cancer. The SIR for cancer was 1.04 (95{\%} CI 0.91 to 1.18) among patients of all ages with pSS and was 2.19 (95{\%} CI 1.43 to 3.21) for patients aged 25-44 years. Female patients with pSS had a higher risk of NHL (SIR 7.1, 95{\%} CI 4.3 to 10.3), multiple myeloma (SIR 6.1, 95{\%} CI 2.0 to 14.2) and thyroid gland cancer (SIR 2.6, 95{\%} CI 1.4 to 4.3) and a lower risk of colon cancer (SIR 0.22, 95{\%} CI 0.05 to 0.65). In contrast, male patients with pSS were not at a higher risk of developing cancer in particular sites. Conclusion: Patients with pSS, overall, did not have higher risk of cancer, and only patients aged 25-44 years were at an increased risk of cancer compared with their counterparts in the general population. Cancer screening for patients with pSS, especially female patients, should focus on NHL and multiple myeloma and thyroid gland cancer.",
author = "Weng, {Meng Yu} and Huang, {Yu Tung} and Liu, {Ming Fei} and Lu, {Tsung Hsueh}",
year = "2012",
month = "4",
day = "1",
doi = "10.1136/annrheumdis-2011-200402",
language = "English",
volume = "71",
pages = "524--527",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "4",

}

Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren's syndrome in Taiwan. / Weng, Meng Yu; Huang, Yu Tung; Liu, Ming Fei; Lu, Tsung Hsueh.

In: Annals of the Rheumatic Diseases, Vol. 71, No. 4, 01.04.2012, p. 524-527.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren's syndrome in Taiwan

AU - Weng, Meng Yu

AU - Huang, Yu Tung

AU - Liu, Ming Fei

AU - Lu, Tsung Hsueh

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Objective: Patients with primary Sjögren's syndrome (pSS) are at a higher risk of developing non-Hodgkin's lymphoma (NHL). However, little is known with regard to the risk of developing cancers other than NHL. The authors aimed in this study to compare the incidence of cancer in various sites among patients with pSS with the general population of Taiwan. Methods: The authors used National Health Insurance claims data to establish a nationwide population cohort of 7852 patients with pSS from 2000 to 2008 who did not have cancer prior to diagnosis of pSS. Incidence and standardised incidence ratios (SIRs) for cancer in various sites were calculated. Results: Among patients with pSS, 277 (2.9%) developed cancer. The SIR for cancer was 1.04 (95% CI 0.91 to 1.18) among patients of all ages with pSS and was 2.19 (95% CI 1.43 to 3.21) for patients aged 25-44 years. Female patients with pSS had a higher risk of NHL (SIR 7.1, 95% CI 4.3 to 10.3), multiple myeloma (SIR 6.1, 95% CI 2.0 to 14.2) and thyroid gland cancer (SIR 2.6, 95% CI 1.4 to 4.3) and a lower risk of colon cancer (SIR 0.22, 95% CI 0.05 to 0.65). In contrast, male patients with pSS were not at a higher risk of developing cancer in particular sites. Conclusion: Patients with pSS, overall, did not have higher risk of cancer, and only patients aged 25-44 years were at an increased risk of cancer compared with their counterparts in the general population. Cancer screening for patients with pSS, especially female patients, should focus on NHL and multiple myeloma and thyroid gland cancer.

AB - Objective: Patients with primary Sjögren's syndrome (pSS) are at a higher risk of developing non-Hodgkin's lymphoma (NHL). However, little is known with regard to the risk of developing cancers other than NHL. The authors aimed in this study to compare the incidence of cancer in various sites among patients with pSS with the general population of Taiwan. Methods: The authors used National Health Insurance claims data to establish a nationwide population cohort of 7852 patients with pSS from 2000 to 2008 who did not have cancer prior to diagnosis of pSS. Incidence and standardised incidence ratios (SIRs) for cancer in various sites were calculated. Results: Among patients with pSS, 277 (2.9%) developed cancer. The SIR for cancer was 1.04 (95% CI 0.91 to 1.18) among patients of all ages with pSS and was 2.19 (95% CI 1.43 to 3.21) for patients aged 25-44 years. Female patients with pSS had a higher risk of NHL (SIR 7.1, 95% CI 4.3 to 10.3), multiple myeloma (SIR 6.1, 95% CI 2.0 to 14.2) and thyroid gland cancer (SIR 2.6, 95% CI 1.4 to 4.3) and a lower risk of colon cancer (SIR 0.22, 95% CI 0.05 to 0.65). In contrast, male patients with pSS were not at a higher risk of developing cancer in particular sites. Conclusion: Patients with pSS, overall, did not have higher risk of cancer, and only patients aged 25-44 years were at an increased risk of cancer compared with their counterparts in the general population. Cancer screening for patients with pSS, especially female patients, should focus on NHL and multiple myeloma and thyroid gland cancer.

UR - http://www.scopus.com/inward/record.url?scp=84857913542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857913542&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2011-200402

DO - 10.1136/annrheumdis-2011-200402

M3 - Article

C2 - 22072014

AN - SCOPUS:84857913542

VL - 71

SP - 524

EP - 527

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 4

ER -